CHROMADEX CORP (CDXC) Fundamental Analysis & Valuation

NASDAQ:CDXC • US1710774076

Current stock price

7.87 USD
-0.07 (-0.88%)
At close:
7.87 USD
0 (0%)
After Hours:

This CDXC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CDXC Profitability Analysis

1.1 Basic Checks

  • CDXC had positive earnings in the past year.
  • CDXC had a positive operating cash flow in the past year.
  • CDXC had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CDXC reported negative operating cash flow in multiple years.
CDXC Yearly Net Income VS EBIT VS OCF VS FCFCDXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • With an excellent Return On Assets value of 12.52%, CDXC belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • CDXC has a Return On Equity of 18.55%. This is amongst the best in the industry. CDXC outperforms 90.91% of its industry peers.
  • CDXC's Return On Invested Capital of 12.13% is amongst the best of the industry. CDXC outperforms 89.09% of its industry peers.
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROIC 12.13%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
CDXC Yearly ROA, ROE, ROICCDXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • CDXC has a Profit Margin of 8.58%. This is in the better half of the industry: CDXC outperforms 74.55% of its industry peers.
  • With a decent Operating Margin value of 7.76%, CDXC is doing good in the industry, outperforming 63.64% of the companies in the same industry.
  • CDXC's Gross Margin of 61.84% is amongst the best of the industry. CDXC outperforms 87.27% of its industry peers.
  • In the last couple of years the Gross Margin of CDXC has grown nicely.
Industry RankSector Rank
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
CDXC Yearly Profit, Operating, Gross MarginsCDXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CDXC Health Analysis

2.1 Basic Checks

  • CDXC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, CDXC has more shares outstanding
  • The number of shares outstanding for CDXC has been increased compared to 5 years ago.
  • Compared to 1 year ago, CDXC has an improved debt to assets ratio.
CDXC Yearly Shares OutstandingCDXC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDXC Yearly Total Debt VS Total AssetsCDXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 15.46 indicates that CDXC is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 15.46, CDXC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.46
ROIC/WACC1.11
WACC10.97%
CDXC Yearly LT Debt VS Equity VS FCFCDXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
  • CDXC has a Current ratio of 3.57. This is comparable to the rest of the industry: CDXC outperforms 54.55% of its industry peers.
  • A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
  • The Quick ratio of CDXC (3.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.06
CDXC Yearly Current Assets VS Current LiabilitesCDXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CDXC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 242.86% over the past year.
  • Looking at the last year, CDXC shows a quite strong growth in Revenue. The Revenue has grown by 19.17% in the last year.
  • Measured over the past years, CDXC shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%

3.2 Future

  • Based on estimates for the next years, CDXC will show a very strong growth in Earnings Per Share. The EPS will grow by 43.55% on average per year.
  • The Revenue is expected to grow by 19.24% on average over the next years. This is quite good.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CDXC Yearly Revenue VS EstimatesCDXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CDXC Yearly EPS VS EstimatesCDXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. CDXC Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 78.70 indicates a quite expensive valuation of CDXC.
  • The rest of the industry has a similar Price/Earnings ratio as CDXC.
  • When comparing the Price/Earnings ratio of CDXC to the average of the S&P500 Index (25.23), we can say CDXC is valued expensively.
  • With a Price/Forward Earnings ratio of 66.13, CDXC can be considered very expensive at the moment.
  • CDXC's Price/Forward Earnings is on the same level as the industry average.
  • CDXC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.42.
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
CDXC Price Earnings VS Forward Price EarningsCDXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CDXC is valued a bit cheaper than 61.82% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CDXC is valued a bit cheaper than 65.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 51.22
EV/EBITDA 66.44
CDXC Per share dataCDXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDXC does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of CDXC may justify a higher PE ratio.
  • CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDXC Dividend Analysis

5.1 Amount

  • No dividends for CDXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CDXC Fundamentals: All Metrics, Ratios and Statistics

CHROMADEX CORP

NASDAQ:CDXC (3/18/2025, 8:00:02 PM)

After market: 7.87 0 (0%)

7.87

-0.07 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04
Earnings (Next)05-06
Inst Owners30.29%
Inst Owner Change1.22%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
P/S 6.14
P/FCF 51.22
P/OCF 50.53
P/B 13.27
P/tB 13.38
EV/EBITDA 66.44
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROCE 15.35%
ROIC 12.13%
ROICexc 104.84%
ROICexgc 111.73%
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
FCFM 11.99%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 20.02%
Cap/Sales 0.16%
Interest Coverage 7726
Cash Conversion 141.79%
Profit Quality 139.72%
Current Ratio 3.57
Quick Ratio 3.06
Altman-Z 15.46
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A

CHROMADEX CORP / CDXC Fundamental Analysis FAQ

What is the fundamental rating for CDXC stock?

ChartMill assigns a fundamental rating of 6 / 10 to CDXC.


Can you provide the valuation status for CHROMADEX CORP?

ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.


Can you provide the profitability details for CHROMADEX CORP?

CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.


Can you provide the financial health for CDXC stock?

The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.


What is the expected EPS growth for CHROMADEX CORP (CDXC) stock?

The Earnings per Share (EPS) of CHROMADEX CORP (CDXC) is expected to grow by 19% in the next year.